856166-98-8

Upstream product

• 258273-31-3 3-cyano-4-isopropoxybenzoic acid 
• 856165-75-8 3-[5-(N-hydroxycarbamimidoyl)-6-methyl-pyridin-2-yl]-propionic acid tert-butyl ester 
• 856165-76-9 2-methyl-3-benzyloxy-6-iodopyridine 
• 856165-80-5 tert-butyl 3-(5-cyano-6-methylpyridin-2-yl)propanoate 
• 856165-78-1 tert-butyl 3-(5-hydroxy-6-methylpyridin-2-yl)propanoate 
• 929202-17-5 3-(5-benzyloxy-6-methyl-pyridin-2-yl)-acrylic acid tert-butyl ester 
• 856165-79-2 tert-butyl 3-(5-trifluoromethylsulfonyloxy-6-methylpyridin-2-yl)propanoate 
• 848952-39-6 6-iodo-2-methylpyridin-3-ol 
• 1121-25-1 2-methyl-3-pyridinol 

Relevant academic research and scientific papers

SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties

Structure-activity relationship (SAR) studies of 3-arylpropionic acids-a class of novel S1P1 selective agonists-by introducing substitution to the propionic acid chain and replacing the adjacent phenyl ring with pyridine led to a series of modi

(3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS

The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.